胃部・胃食道接合部腺癌：世界の薬剤市場予測・分析...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 23
2 Introduction 26
2.1 Catalyst 26
2.2 Related Reports 27
2.3 Upcoming Related Reports 27
3 Disease Overview 28
3.1 Etiology and Pathophysiology 28
3.1.1 Etiology 28
3.1.2 Pathophysiology 28
3.1.3 Biomarkers/Targets of Interest 30
3.2 Staging 31
3.3 Symptoms 33
3.4 Prognosis 33
3.5 Quality of Life 34
4 Epidemiology 36
4.1 Disease Background 36
4.2 Risk Factors and Comorbidities 37
4.3 Global Trends 38
4.3.1 8MM, Incidence Trends 39
4.4 Forecast Methodology 41
4.4.1 Sources Used 47
4.4.2 Sources Not Used 55
4.4.3 Forecast Assumptions and Methods, Diagnosed Incident Cases of Gastric Cancer – 8MM 56
4.4.4 Forecast Assumptions and Methods, Five-Year Diagnosed Prevalent Cases of Gastric Cancer – 8MM 57
4.4.5 Forecast Assumptions and Methods, Gastric Cancer Clinical Stages at Diagnosis – 8MM 58
4.4.6 Forecast Assumptions and Methods, Gastric Cancer Cellular Types – 8MM 59
4.4.7 Forecast Assumptions and Methods, HER2 Status – 8MM 61
4.4.8 Forecast Assumptions and Methods, Diagnosed Incident Cases of GEJ Cancer – 8MM 62
4.4.9 Forecast Assumptions and Methods, Diagnosed Incident Cases of Gastric Adenocarcinomas – 8MM 64
4.5 Epidemiological Forecast of Gastric Cancer (2014-2024) 64
4.5.1 Diagnosed Incident Cases of Gastric Cancer 64
4.5.2 Age-Specific Diagnosed Incident Cases of Gastric Cancer 66
4.5.3 Sex-Specific Diagnosed Incident Cases of Gastric Cancer 67
4.5.4 Age-Standardized Diagnosed Incidence of Gastric Cancer 69
4.5.5 Percentage Distribution of Diagnosed Incident Cases of Gastric Cancer, by Stage at Diagnosis 70
4.5.6 Percentage Distribution of Diagnosed Incident Cases of Gastric Cancer, by Cellular Type 71
4.5.7 Diagnosed Incident Cases of Gastric Cancer by HER2 Status 72
4.5.8 Diagnosed Incident Cases of GEJ Cancer 74
4.5.9 Five-Year Diagnosed Prevalent Cases of Gastric Cancer 76
4.6 Discussion 77
4.6.1 Epidemiological Forecast Insight 77
4.6.2 Limitations of the Analysis 78
4.6.3 Strengths of the Analysis 79
5 Disease Management 80
5.1 Diagnosis and Treatment Overview 80
5.1.1 Screening 80
5.1.2 Diagnosis 81
5.1.3 Treatment Guidelines and Leading Prescribed Drugs 85
5.1.4 Clinical Practice 85
5.2 US 96
5.2.1 Screening and Diagnosis 97
5.2.2 Clinical Practice 97
5.3 France 99
5.3.1 Screening and Diagnosis 100
5.3.2 Clinical Practice 101
5.4 Germany 101
5.4.1 Screening and Diagnosis 102
5.4.2 Clinical Practice 103
5.5 Italy 104
5.5.1 Screening and Diagnosis 105
5.5.2 Clinical Practice 105
5.6 Spain 106
5.6.1 Screening and Diagnosis 107
5.6.2 Clinical Practice 107
5.7 UK 108
5.7.1 Screening and Diagnosis 109
5.7.2 Clinical Practice 109
5.8 Japan 110
5.8.1 Screening and Diagnosis 111
5.8.2 Clinical Practice 113
5.9 China 118
5.9.1 Screening and Diagnosis 119
5.9.2 Clinical Practice 120
6 Competitive Assessment 125
6.1 Overview 125
6.2 HER2-Targeted Therapy 126
6.2.1 Herceptin (trastuzumab) 126
6.3 Angiogenesis Inhibitors 137
6.3.1 Cyramza (ramucirumab) 137
6.3.2 Aitan (apatinib) 149
6.4 Chemotherapies 155
6.4.1 TS-1 (tegafur, gimeracil, oteracil) 155
6.4.2 Abraxane (nab-paclitaxel) 166
7 Unmet Need and Opportunity 173
7.1 Overview 173
7.2 First-Line Therapy for HER2-Negative Patients 174
7.2.1 Unmet Need 174
7.2.2 Gap Analysis 175
7.2.3 Opportunity 176
7.3 New Molecular Targets for Targeted Therapies 176
7.3.1 Unmet Need 176
7.3.2 Gap Analysis 177
7.3.3 Opportunity 178
7.4 Effective Perioperative and Postoperative Therapies 181
7.4.1 Unmet Need 181
7.4.2 Gap Analysis 182
7.4.3 Opportunity 183
7.5 More Efficacious HER2-Targeted Therapies 184
7.5.1 Unmet Need 184
7.5.2 Gap Analysis 185
7.5.3 Opportunity 186
7.6 Peritoneal Metastases 187
7.6.1 Unmet Need 187
7.6.2 Gap Analysis 188
7.6.3 Opportunity 189
7.7 Better Clinical Trial Design 190
7.7.1 Unmet Need 190
7.7.2 Gap Analysis 190
7.7.3 Opportunity 191
7.8 Early Detection of Gastric and Gastroesophageal Adenocarcinomas 193
7.8.1 Unmet Need 193
7.8.2 Gap Analysis 194
7.8.3 Opportunity 195
8 Pipeline Assessment 196
8.1 Overview 196
8.2 Promising Drugs in Phase III Clinical Development 197
8.3 HER2-Targeted Therapies 198
8.3.1 Kadcyla (T-DM1; trastuzumab emtansine) 198
8.3.2 Perjeta (pertuzumab) 203
8.4 Immune Checkpoint Inhibitors 211
8.4.1 Keytruda (pembrolizumab) 211
8.4.2 Opdivo (nivolumab) 218
8.5 Further Strategies for G/GEJAC Treatment 224
8.5.1 Napabucasin 224
8.5.2 Lynparza (olaparib) 231
8.5.3 Nimotuzumab 239
8.5.4 TAS-118 247
8.6 Early/Near-Phase III Pipeline Drugs 252
8.6.1 GS-5745 252
8.6.2 Masitinib 256
8.7 Promising Drugs in Early-Stage Development 261
8.7.1 Immune Checkpoint Inhibitors 261
8.7.2 MET-Targeting Drugs 263
8.7.3 Antibody-Drug Conjugates 265
8.8 Biosimilars 269
9 Current and Future Players 272
9.1 Overview 272
9.2 Trends in Corporate Strategy 275
9.3 Company Profiles 276
9.3.1 Bristol-Myers Squibb 276
9.3.2 Eli Lilly and Company 279
9.3.3 Merck & Co. 282
9.3.4 Roche 285
9.3.5 Taiho Pharmaceutical 289
9.3.6 Sumitomo Dainippon Pharma 291
10 Market Outlook 294
10.1 Global Markets 294
10.1.1 Forecast 294
10.1.2 Drivers and Barriers – Global Issues 298
10.2 US 301
10.2.1 Forecast 301
10.2.2 Key Events 305
10.2.3 Drivers and Barriers – US 305
10.3 5EU 308
10.3.1 Forecast 308
10.3.2 Key Events 312
10.3.3 Drivers and Barriers – France 312
10.3.4 Drivers and Barriers – Germany 315
10.3.5 Drivers and Barriers – Italy 317
10.3.6 Drivers and Barriers – Spain 319
10.3.7 Drivers and Barriers – UK 321
10.4 Japan 324
10.4.1 Forecast 324
10.4.2 Key Events 328
10.4.3 Drivers and Barriers – Japan 328
10.5 China 331
10.5.1 Forecast 331
10.5.2 Key Events 335
10.5.3 Drivers and Barriers – China 335
11 Appendix 339
11.1 Bibliography 339
11.2 Abbreviations 374
11.3 Methodology 382
11.4 Forecasting Methodology 382
11.4.1 Diagnosed G/GEJAC Patients 382
11.4.2 Percent of Drug-Treated Patients 383
11.4.3 Drugs Included in Each Therapeutic Class 383
11.4.4 Launch and Patent Expiry Dates 384
11.4.5 General Pricing Assumptions 385
11.4.6 Individual Drug Assumptions 387
11.4.7 Generic Erosion 400
11.4.8 Pricing of Pipeline Agents 400
11.5 Primary Research – Key Opinion Leaders Interviewed for this Report 402
11.6 Primary Research – High-Prescriber Survey 405
11.7 About the Authors 406
11.7.1 Analyst 406
11.7.2 Therapy Area Director 406
11.7.3 Epidemiologist 407
11.7.4 Global Head of Healthcare 407
11.8 About GlobalData 408
11.9 Disclaimer 408